Workflow
和元生物(688238) - 2023 Q3 - 季度财报
OBiO TechOBiO Tech(SH:688238)2023-10-25 16:00

Financial Performance - The company's operating revenue for Q3 2023 was ¥53,243,301.82, a decrease of 33.80% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥26,301,678.77, representing a decline of 289.38% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥29,088,687.39, down 355.09% from the previous year[5]. - Cumulative operating revenue for the year reached ¥136,994,292.35, a decrease of 36.38% compared to the same period last year[7]. - The company reported a basic and diluted earnings per share of -¥0.041, a decrease of 286.36% year-on-year[6]. - The total comprehensive income attributable to the parent company for Q3 2023 was -70,508,186.16 RMB, compared to 33,914,132.42 RMB in Q3 2022, indicating a significant decline[29]. - Basic and diluted earnings per share for Q3 2023 were both -0.111 RMB, down from 0.057 RMB in Q3 2022[29]. - The net profit for the third quarter of 2023 was a loss of ¥71,004,439.21, compared to a profit of ¥33,914,132.42 in the same quarter of 2022[28]. - Operating profit for the first three quarters of 2023 was a loss of ¥87,679,634.77, down from a profit of ¥36,300,707.29 in the previous year[27]. - The net profit for the third quarter was a loss of ¥58,272,791.28, compared to a profit of ¥34,430,928.55 in the same quarter of 2022[34]. Research and Development - Research and development expenses totaled ¥14,242,102.87, accounting for 26.75% of operating revenue, an increase of 14.85 percentage points year-on-year[6]. - Total R&D investment for the current reporting period is 48.79 million, and for the year-to-date is 62.47 million, attributed to the expansion of the R&D team and increased project investments[12]. - Research and development expenses rose to ¥38,580,900.32 from ¥23,746,842.11 year-over-year, indicating increased investment in innovation[27]. - Research and development expenses for the first three quarters of 2023 amounted to ¥34,374,084.37, an increase from ¥20,990,633.73 in the same period last year[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,621,496,594.20, an increase of 5.28% from the end of the previous year[6]. - The total assets of the company as of the third quarter of 2023 amounted to ¥2,621,496,594.20, compared to ¥2,490,077,914.30 in the previous year[23]. - Total liabilities increased to ¥501,168,612.77 from ¥318,879,989.48 year-over-year, reflecting a rise in financial obligations[23]. - The company's equity attributable to shareholders was ¥2,120,232,850.10, a slight decrease from ¥2,171,197,924.82 in the previous year[23]. - The total current assets as of September 30, 2023, were 1,064,767,783.53 RMB, a decrease from 1,211,175,937.45 RMB at the end of 2022[31]. - Long-term equity investments increased to 67,477,500.39 RMB as of September 30, 2023, compared to 42,223,677.39 RMB at the end of 2022[21]. Cash Flow - The cash flow from operating activities showed a significant decline, impacting the overall financial health of the company[27]. - Cash inflows from operating activities for the first three quarters of 2023 totaled 177,897,526.64 RMB, a decrease from 200,377,025.70 RMB in the same period of 2022[30]. - Net cash flow from operating activities for Q3 2023 was -79,220,727.00 RMB, compared to -1,654,985.31 RMB in Q3 2022, reflecting a worsening cash flow situation[30]. - Operating cash flow for the first three quarters of 2023 was negative at -265,393,513.23 RMB, compared to a positive cash flow of 2,815,728.97 RMB in the same period of 2022[36]. - Total cash inflow from operating activities decreased to 160,685,551.18 RMB in 2023 from 197,020,962.62 RMB in 2022, representing a decline of approximately 18.4%[36]. - Cash outflow from operating activities increased significantly to 426,079,064.41 RMB in 2023, up from 194,205,233.65 RMB in 2022, marking an increase of about 119.5%[36]. Shareholder Information - As of September 30, 2023, the total number of ordinary shareholders is 11,684[15]. - The top 10 shareholders hold a total of 286,000,000 shares, representing approximately 43.93% of the total shares[15]. - The company has a total of 741 employees as of September 30, 2023, excluding interns and labor personnel[18]. Strategic Initiatives - The company is focusing on long-term development strategies and increasing R&D investment, which has led to higher operational costs and a decline in gross profit and net profit[7]. - The company anticipates improved capacity and market expansion as the Lingang base begins operations and new orders are signed[7]. - The company plans to focus on market expansion and new product development to improve future performance[28]. - The company plans to focus on new product development and market expansion strategies moving forward[35]. - The company plans to establish an industrial investment fund with a maximum investment of 20 million RMB, which is currently in the preparatory stage[20]. Patents and Trademarks - The company has obtained a total of 23 invention patents, 6 utility model patents, and 57 domestic registered trademarks as of September 30, 2023[18]. Production Capacity - The first phase of the GMP production base, covering nearly 80,000 square meters, has commenced production, enhancing the company's ability to meet global CDMO demand[20].